The patent was filed in Europe, hence the abstract got published (even though it is pending). Pending because it did not issue yet, places filed were listed in the abstract. Source: Chemical Abstracts.
Manufacturing is not easy, but this info is indirect (this and Yahoo threads). In this case I read them all, they're not that numerous. I guess they get a lot of junk during expression. They don't talk too much in public. You probably know that GMP commercial scale is their most difficult task ahead. I think they'll get it solved, even if it has to be chemical synthesis, plant expression, mammalian, enzymatic cleavage of collagen, bacteria, etc.
Because NCI will help them, they'll get the resources (brains, money, network, work, intellectual property, etc.). That's the coolest form of public financing of a private industry (see Boeing, Lockheed, etc.). Even Congress or the White House may get involved, as they got involved in far less significant medical businesses. I can imagine big tobacco jumping in, eventually.
As I observed ENMD quite thoroughly in the past few years or so. They are not in a hurry to sell themselves or their best things. They may be sorry they had to get a deal with BMS but they probably needed help. In fact, I think these guys dream of becoming fully integrated Big Pharma, another Amgen, or even Pfizer. I well may happen.
Regards,
StockDoc |
